Short Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Increases By 88.0%

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 36,835 shares, an increase of 88.0% from the May 14th total of 19,598 shares. Based on an average daily trading volume, of 59,827 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.7% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on NEUP shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Monday, June 1st. HC Wainwright cut shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $21.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEUP. Persistent Asset Partners Ltd bought a new position in Neuphoria Therapeutics during the third quarter valued at approximately $58,000. Millennium Management LLC bought a new position in Neuphoria Therapeutics during the third quarter valued at approximately $216,000. FNY Investment Advisers LLC bought a new position in Neuphoria Therapeutics during the fourth quarter valued at approximately $102,000. Geode Capital Management LLC increased its holdings in Neuphoria Therapeutics by 33.3% during the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after buying an additional 4,325 shares during the last quarter. Finally, AdvisorShares Investments LLC increased its holdings in Neuphoria Therapeutics by 129.1% during the fourth quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock valued at $521,000 after buying an additional 75,631 shares during the last quarter. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Stock Up 1.8%

Shares of Neuphoria Therapeutics stock opened at $4.45 on Monday. The company has a market cap of $24.03 million, a price-to-earnings ratio of -0.40 and a beta of 0.72. The company’s 50 day moving average is $4.92 and its 200 day moving average is $4.44. Neuphoria Therapeutics has a twelve month low of $3.64 and a twelve month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. Sell-side analysts expect that Neuphoria Therapeutics will post -4.07 EPS for the current fiscal year.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.